On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape
Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia
Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.
Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia
Dr Cassaday discusses data supporting the use of combination blinatumomab and pembrolizumab in patients with R/R ALL.
Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia
Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.
CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia
Dr Schiller summarizes results from the ZUMA-3 trial and poses thoughtful questions to fellow panelists regarding clinical significance.
Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.
Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.
The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Gary J. Schiller, MD and fellow panelists discuss clinical trial outcomes presented at the ASH 2022 annual meeting relevant to patients with Philadelphia chromosome-positive ALL.
Treatment Options for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Frontline Setting
Focusing on Philadelphia chromosome-positive ALL, panelists review standard-of-care treatment practices.
Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia
Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.
Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
Ryan Cassaday, MD, notes differences between prognoses for patients with ALL based-on age, subtype, and disease progression status.
Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia
Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.
Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia
A panel of experts briefly reviews how both pediatric and adult patients with acute lymphoblastic leukemia (ALL) typically present and describes a standard patient workup.
Differentiating Subtypes of Acute Lymphoblastic Leukemia
Elias Jabbour, MD, leads a discussion on the similarities and differences between ALL subtypes and their respective incidence rates.
ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia
Evolving Field of Acute Lymphoblastic Leukemia
Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia
CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia
CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia
Approach to Managing Relapsed Acute Lymphoblastic Leukemia
Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia
Managing MRD-Negative Acute Lymphoblastic Leukemia
Managing MRD-Positive Acute Lymphoblastic Leukemia
Treatment of Acute Lymphoblastic Leukemia in the Community Setting
Role of MRD Testing in Acute Lymphoblastic Leukemia
Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL
Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL
Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL
Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL
Prognostic Factors Which Impact ALL Management
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512